Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer

Current Medical Research and Opinion
Rohit MistryAnand A Dalal

Abstract

The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This study evaluates the budget impact of using the CDK 4/6 inhibitor ribociclib plus letrozole as a first-line treatment option for postmenopausal women with HR+/HER2- advanced breast cancer, from a United States (US) payer perspective. A cohort-based budget impact model was used to calculate the incremental cost of introducing ribociclib plus letrozole over three years for the target population. The analysis compared two scenarios: treatment options excluding or including ribociclib plus letrozole. Market shares were derived from market research and the assumption was the introduction of ribociclib plus letrozole would only displace existing CDK-based therapies. Treatment duration was based on the median time to treatment discontinuation or median progression-free survival for first-line treatment, and on clinical trial data for second- and third-line treatment. Acquisition costs were based on wholesale acquisition costs and considered co...Continue Reading

References

Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Jun 12, 2012·Breast Cancer Research and Treatment·Alberto J MonteroPaulette Adler
Jul 19, 2012·PharmacoEconomics·Shannon L MichelsGary H Lyman
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew J EllisJohn F R Robertson
Mar 10, 2016·Journal of the National Comprehensive Cancer Network : JNCCN·William J GradisharRashmi Kumar
Mar 20, 2016·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Paul Brown
May 6, 2016·JAMA : the Journal of the American Medical Association·Sham Mailankody, Vinay Prasad
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Mar 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Debu TripathyWilliam R Sellers
May 5, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MamiyaM Najafzadeh
Jul 26, 2017·Breast Cancer Research and Treatment·Dorota Kwapisz
May 3, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G N HortobagyiJ O'Shaughnessy
Jun 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dennis J SlamonGuy Jerusalem

❮ Previous
Next ❯

Citations

Dec 14, 2018·The Annals of Pharmacotherapy·Kaitlin RasconEkim Ekinci
Dec 29, 2020·Cancer Management and Research·Jiangping YangXi Yan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.